FDA Approval Alert: The Need-to-Know | Axatilimab in Pediatric/Adult Chronic GVHD

In August 2024, the FDA approved axatilimab-csfr for patients who weigh at least 40 kg with chronic graft-versus-host disease after progression on 2 prior lines of systemic therapy.